A Single-center, Single-arm Phase II Study of Limertinib Plus Carboplatin and Etoposide in EGFR-mutant NSCLC Patients With SCLC Transformation After EGFR-TKI Progression
Latest Information Update: 10 Jun 2025
At a glance
- Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Limertinib (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Jun 2025 New trial record